6533b852fe1ef96bd12ab6cb

RESEARCH PRODUCT

Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir

Veronika WeyerArno SchadSebastian BernuthMartin F. SprinzlEray YagmurTim ZimmermannJörn M. SchattenbergAnca ZimmermannJ KnapsteinJens M. KittnerDetlef SchuppanPeter R. GalleMarcus A. Wörns

subject

Liver CirrhosisMaleNon-invasive serum markersmedicine.medical_specialtySofosbuvirLiver fibrosisHepatitis C virusLiver fibrosisHepacivirusmedicine.disease_causeAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineFibrosisInternal medicinemedicineHumansAspartate AminotransferasesProspective StudiesLiver stiffness measurementHepatitisFibroScanHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyHepatitis CHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseTreatment OutcomeELF030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinomaElasticity Imaging TechniquesRNA ViralFemale030211 gastroenterology & hepatologySofosbuvirbusinessmedicine.drug

description

Abstract Background Chronic hepatitis C is a major cause of liver-associated mortality caused by decompensated cirrhosis and hepatocellular carcinoma. With the approval of sofosbuvir, therapeutic efficacy has markedly increased. Early changes in non-invasive biomarkers of liver fibrosis under effective antiviral therapy are widely unknown. Aim To evaluate early changes of fibrosis markers determined by enhanced liver fibrosis (ELF) scores and liver stiffness measurement (FibroScan®) in patients treated with sofosbuvir. Methods A total of 32 hepatitis C patients treated prospectively with sofosbuvir were included. The ELF-panel and FibroScan measurements were performed at baseline, week 4, end-of-treatment and 12 weeks thereafter. Results Antiviral therapy resulted in a biochemical and virological response within 4 weeks. Sustained virological response rate at 12-week follow-up (SVR12) was 93.8%; there was a significantly decrease from baseline to 12-week post-treatment follow-up in ELF (10.00 vs. 9.37; p = 0.007) and FibroScan (8.0 vs. 6.8 kPa; p = 0.016) measurements, indicating improvement of the dynamics of liver fibrosis. Conclusion We observed a rapid decrease in non-invasive fibrosis markers measured by ELF-scores and FibroScan in hepatitis C-infected patients receiving sofosbuvir treatment. These initial results need to be histologically confirmed by liver biopsy in the future.

yearjournalcountryeditionlanguage
2016-03-01Digestive and Liver Disease
https://doi.org/10.1016/j.dld.2015.09.015